Publication:
Unrecognised cardiovascular disease in type 2 diabetes: Is it time to act earlier?

dc.contributor.authorSchernthaner, Guntram (7101681229)
dc.contributor.authorLotan, Chaim (7005954879)
dc.contributor.authorBaltadzhieva-Trendafilova, Elina (55396473400)
dc.contributor.authorCeponis, Jonas (23495190700)
dc.contributor.authorClodi, Martin (7003534674)
dc.contributor.authorDucena, Kristine (36702447500)
dc.contributor.authorGoncalvesova, Eva (55940355200)
dc.contributor.authorGuja, Cristian (6603582360)
dc.contributor.authorHonka, Marek (24366583700)
dc.contributor.authorJanež, Andrej (6603143804)
dc.contributor.authorLalić, Nebojša (13702597500)
dc.contributor.authorLehmann, Roger (14022858600)
dc.contributor.authorNyolczas, Noémi (24388812000)
dc.contributor.authorPauklin, Priit (57204737562)
dc.contributor.authorRynkiewicz, Andrzej (56261255000)
dc.contributor.authorSergienko, Igor (36440217900)
dc.contributor.authorDuvnjak, Lea Smirčić (6508009486)
dc.date.accessioned2025-06-12T15:58:47Z
dc.date.available2025-06-12T15:58:47Z
dc.date.issued2018
dc.description.abstractCardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be 'silent' or 'asymptomatic', but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology used to describe this phenomenon. By standardising the terminologies, and agreeing on the implementation of an efficient screening program, it is anticipated that patients will receive an earlier diagnosis and appropriate and timely treatment. Given the availability of anti-diabetic medications that have been shown to concomitantly reduce CV risk and mortality, it is imperative to improve early identification and initiate treatment as soon as possible in order to enable as many patients with T2D as possible to benefit. © 2018 The Author(s).
dc.identifier.urihttps://doi.org/10.1186/s12933-018-0788-7
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85056977005&doi=10.1186%2fs12933-018-0788-7&partnerID=40&md5=9cef401410210e81f1155a5a4b9c10a9
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/6052
dc.subjectAsymptomatic
dc.subjectAtypical
dc.subjectCardiovascular disease
dc.subjectScreening
dc.subjectSilent
dc.subjectType 2 diabetes
dc.subjectUnrecognised
dc.titleUnrecognised cardiovascular disease in type 2 diabetes: Is it time to act earlier?
dspace.entity.typePublication

Files